Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MME | P08473 | 14/20 | 1.00 |
| ▸ | ACE | P12821 | 7/20 | 1.00 |
| ▸ | MMEL1 | Q495T6 | 3/20 | 0.80 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lbq-657 SCHEMBL9565416 | 1.00 | MME (1.00) | MMEACEMMEL1 | |
| Lbq-657 SCHEMBL1908575 | 1.00 | MME (1.00) | MMEACEMMEL1 | |
| Lbq-657 SCHEMBL7433849 | 1.00 | MME (1.00) | MMEACEMMEL1 | |
| Lbq-657 SCHEMBL391633 | 1.00 | MME (1.00) | MMEACEMMEL1 | |
| SCHEMBL9565424 | 0.93 | MME (0.86) | MMEACEMMEL1 | |
| SCHEMBL9565420 | 0.93 | MME (0.86) | MMEACEMMEL1 | |
| SCHEMBL7441588 | 0.91 | MME (0.84) | MMEACEMMEL1 | |
| SCHEMBL18396712 | 0.90 | MME (0.81) | MMEACEMMEL1 | |
| SCHEMBL9565409 | 0.90 | MME (0.81) | MMEACEMMEL1 | |
| SCHEMBL22556618 | 0.89 | MME (0.80) | MMEACEMMEL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 388 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-112641773-A | Composition containing heterocyclic compound and use thereof | 黄泳华 | 2021-04-13 | — | — | CN | claimed |
| CN-111265518-A | Composition containing a mixture of biphenyl derivatives and uses thereof | 黄泳华 | 2020-06-12 | — | — | CN | claimed |
| CN-111110854-A | Composition comprising a histamine release-promoting substance and an inhibitory compound | 黄泳华 | 2020-05-08 | — | — | CN | claimed |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | INTRA-CELLULAR THERAPIES, INC. (US) | 2019-05-14 | — | — | US | claimed |
| EP-3038653-A1 | NEW USE | Novartis AG (CH) | 2016-07-06 | — | — | EP | claimed |
| WO-2015030711-A1 | NEW USE | NOVARTIS AG (CH) | 2015-03-05 | — | — | WO | claimed |
| US-12453719-B2 | Treatment method using a complex of angiotensin II receptor antagonist metabolite and NEP inhibitor | SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. (CN) | 2025-10-28 | — | — | US | disclosed |
| US-12351561-B2 | Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2025-07-08 | — | — | US | disclosed |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | THERAVANCE BIOPHARMA R&D IP LLC (US) | 2024-10-03 | — | — | US | disclosed |
| US-12016835-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-06-25 | — | — | US | disclosed |
| US-20240165032-A1 | DRUG DELIVERY SYSTEM | EB IP HYBRITABS B V (NL) | 2024-05-23 | — | — | US | disclosed |
| US-11919888-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2024-03-05 | — | — | US | disclosed |
| US-11851443-B2 | Neprilysin inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2023-12-26 | — | — | US | disclosed |
| US-20090093417-A1 | Dual-acting antihypertensive agents | THERAVANCE, INC. | 2009-04-09 | — | — | US | disclosed |
| WO-2009035543-A1 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2009-03-19 | — | — | WO | disclosed |
| US-20090023228-A1 | Dual-acting Imidazole antihypertensive agents | THERAVANCE, INC. | 2009-01-22 | — | — | US | disclosed |
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | THERAVANCE, INC. | 2008-12-25 | — | — | US | disclosed |
| WO-2008153857-A1 | DUAL-ACTING BENZOIMIDAZOLE ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008133896-A2 | DUAL-ACTING ANTIHYPERTENSIVE AGENTS | THERAVANCE, INC. (US) | 2008-11-06 | — | — | WO | disclosed |
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | THERAVANCE, INC. | 2008-10-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090093417-A1 | Dual-acting antihypertensive agents | AGTR1, REN, AGTR2 | MME 5/4885ACE 6/4885MMEL1 720/4885 |
| US-20080269305-A1 | R)-N-{2-Butyl-3-[2'-(2H-tetrazol-5-yl)biphenyl-4-ylmethyl]-3H-imidazol-4-ylmethyl}-2-(2-hydroxycarbamoyl-3-phenyl-propionylamino)succinamic Acid; AT1 receptor antagonist and neprilysin (NEP) enzyme inhibition activity; hypertension, heart failure | AGTR2, REN, AGTR1 | MME 4/4885ACE 7/4885MMEL1 1252/4885 |
| US-12453719-B2 | Treatment method using a complex of angiotensin II receptor antagonist metabolite and NEP inhibitor | MME, AGTR2, ACE | MME 1/4885ACE 3/4885MMEL1 207/4885 |
| US-12351561-B2 | Crystalline (2S,4R)-5-(5'-chloro-2'-fluoro-[1,1'-biphenyl]-4-yl)-2-(ethoxymethyl)-4-(3-hydroxyisoxazole-5-carboxamido)-2-methylpentanoic acid and uses thereof | MME, CTSC, REN | MME 1/4885ACE 4/4885MMEL1 54/4885 |
| US-10285992-B2 | Combinations of PDE1 inhibitors and NEP inhibitors and associated methods | PDE5A, PDE3A, PDE2A | MME 9/4885ACE 34/4885MMEL1 119/4885 |
| US-20240327360-A1 | CRYSTALLINE (2S,4R)-5-(5'-CHLORO-2'-FLUORO-[1,1'-BIPHENYL]-4-YL)-2-(ETHOXYMETHYL)-4-(3-HYDROXYISOXAZOLE-5-CARBOXAMIDO)-2-METHYLPENTANOIC ACID AND USES THEREOF | MME, CTSC, REN | MME 1/4885ACE 4/4885MMEL1 54/4885 |
| US-20090023228-A1 | Dual-acting Imidazole antihypertensive agents | AGTR1, AGTR2, REN | MME 13/4885ACE 6/4885MMEL1 993/4885 |
| US-11851443-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 237/4885 |
| US-12016835-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 213/4885 |
| US-20080318951-A1 | Dual-acting benzoimidazole antihypertensive agents | AGTR1, REN, AGTR2 | MME 6/4885ACE 7/4885MMEL1 1342/4885 |
| US-11919888-B2 | Neprilysin inhibitors | MME, REN, ACE | MME 1/4885ACE 3/4885MMEL1 240/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.